| Type 2 Diabetes Mellitus |
1 |
1 |
| Incretin Hormone |
0 |
0.44 |
| Remission |
0 |
0.44 |
| Type 1 Diabetes Mellitus |
0 |
0.99 |
| Obesity |
0 |
0.4 |
| Renal Disease |
0 |
0.35 |
| Europe |
0 |
0.29 |
| Hypoglycemia |
0 |
0.29 |
| Artificial Pancreas |
0 |
0.21 |
| Fatty Liver |
0 |
0.21 |
| Liver Disease |
0 |
0.21 |
| Chronic Kidney Disease |
0 |
0.2 |
| Hypertension |
0 |
0.19 |
| Biliary Disease |
0 |
0.16 |
| Renal Failure |
0 |
0.16 |
| Cardiovascular disease |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| COVID-19 |
0 |
0.15 |
| COVID-19 and Diabetes |
0 |
0.15 |
| Endocrinology |
0 |
0.15 |
| Hospital |
0 |
0.15 |
| Insulin Resistance |
0 |
0.15 |
| Kidney |
0 |
0.15 |
| Liver |
0 |
0.15 |
| Metabolism |
0 |
0.15 |
| Neuropathy |
0 |
0.15 |
| Pancreas |
0 |
0.15 |
| Receptors |
0 |
0.15 |
| Retinopathy |
0 |
0.15 |
| Salary and Compensation |
0 |
0.15 |
| SGLT2 Inhibitor |
0 |
0.15 |
| Translational Research |
0 |
0.15 |
| Transplantation |
0 |
0.15 |
| Weight Loss |
0 |
0.15 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.12 |
| Cardiomyopathy |
0 |
0.1 |
| Pregnancy |
0 |
0.1 |
| Revenue and Practice Management |
0 |
0.1 |
| Stem Cell Research and Therapy |
0 |
0.1 |
| Cardiovascular Risk Management |
0 |
0.06 |
| Cystic Fibrosis |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Lipids Management |
0 |
0.06 |
| Retinal Diseases |
0 |
0.06 |
| Weight Management |
0 |
0.06 |